Ireland· IE-PA-EU/1/08/502/001
Mepact 4 mg Powder for concentrate for dispersion for infusion
A mifamurtid product containing mifamurtide, registered in Ireland by Esteve Pharmaceuticals S.A.. The same ATC class is registered in 8 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Mifamurtid is registered in 8 of 19 countries.
Countries holding a registration under ATC L03AX15 (mifamurtid), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 5 of them publish a price we can compare per daily dose
Mifamurtid · ATC L03AX15
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
The record
At a glance
HPRA (Ireland)- Active substance
- Mifamurtide
- Manufacturer
- Esteve Pharmaceuticals S.A.
- Country
- Ireland (IE)
- ATC code
- L03AX15
- ATC class
- Mifamurtid
- Defined daily dose
- 0.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/08/502/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mifamurtid in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomMepact 4mg powder for concentrate for dispersion for infusion vialsTakeda UK Ltd
- BelgiumMepact 4 mgEsteve Pharmaceuticals
- FinlandMEPACTEsteve Pharmaceuticals, S.A
- PolandMepactEsteve Pharmaceuticals, S.A.
- SwedenMEPACT 4 mg Pulver till koncentrat till infusionsvätska, dispersionEsteve Pharmaceuticals S.A.
- CzechiaMEPACTEsteve Pharmaceuticals S.A., Barcelona
- SpainMEPACT 4 mg POLVO PARA SUSPENSION PARA PERFUSIONEsteve Pharmaceuticals S.A.
- IcelandMepactEsteve Pharmaceuticals S.A.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Mepact
- Liechtenstein · Mepact
- Norway · Mepact
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5be49351-e41b-471c-b6e9-eddaecc94a7e GET /v1/drugs/5be49351-e41b-471c-b6e9-eddaecc94a7e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for concentrate for dispersion for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"L03AX",
"L03AX15"
],
"strength": null,
"pa_number": "EU/1/08/502/001",
"substances": [
"Mifamurtide"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "06/03/2009",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about mifamurtid.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.